DrugPatentWatch Database Preview
Details for Patent: 8,609,701
» See Plans and Pricing
Which drugs does patent 8,609,701 protect, and when does it expire?
Patent 8,609,701 protects ESBRIET and is included in two NDAs.
This patent has sixty-four patent family members in thirty-nine countries.
Summary for Patent: 8,609,701
| Title: | Pirfenidone treatment for patients with atypical liver function |
| Abstract: | Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone. |
| Inventor(s): | Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
| Assignee: | Intermune, Inc. (Brisbane, CA) |
| Application Number: | 13/128,569 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,609,701 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,609,701
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,609,701
| PCT Information | |||
| PCT Filed | November 09, 2009 | PCT Application Number: | PCT/US2009/063702 |
| PCT Publication Date: | May 14, 2010 | PCT Publication Number: | WO2010/054294 |
International Family Members for US Patent 8,609,701
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 503480 | Start Trial | |||
| Australia | 2009313302 | Start Trial | |||
| Australia | 2010212371 | Start Trial | |||
| Australia | 2011200385 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
